Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LinkSkin Spray is a topical veterinary dermatology product developed by Nextmune to support skin function and restore the skin microbiome in companion animals, including dogs, cats, and puppies. It is specifically indicated for managing skin microflora imbalances, atopic dermatitis, and cutaneous hyper-reactivity. The formulation contains tyndallized lactobacilli (*Lactobacillus rhamnosus* and *Lactobacillus reuteri*), plant polyphenols, tamarind dry extract, and algae extracts. These ingredients work synergistically to restore skin microbiome balance, improve skin homeostasis, and reinforce the skin barrier. Clinical evidence, including a 2021 study in *Veterinary Dermatology*, indicates that LinkSkin Spray significantly and rapidly reduces clinical signs associated with canine atopic dermatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LinkSkin Spray.